Lupin, a pharmaceutical company based in India, made a big announcement on Tuesday. They revealed that they will be using Honeywell’s Solstice Air propellant in their next-generation respiratory inhalers. This makes them the first Indian pharmaceutical company to adopt this technology on a large scale. The goal of this partnership is to revolutionize respiratory care for patients with asthma and COPD, all while making a significant impact on the environment. Honeywell’s HFO-1234ze cGMP propellant is said to reduce greenhouse gas emissions by nearly 99.9%, compared to the traditional hydrofluorocarbon-based propellants commonly used in inhalers.
Vinita Gupta, the CEO of Lupin, expressed her excitement about the partnership with Honeywell. She stated, “Lupin’s partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future.” On the other hand, Jeff Dormo, a president at Honeywell, highlighted the benefits of Solstice Air in ensuring effective treatment for patients while also cutting down on harmful greenhouse gas emissions. The terms of the deal are still being negotiated, and both companies are working on finalizing the agreements.
Lupin has a global presence, with products available in over 100 markets. They are particularly strong in India and the US, offering a range of treatments in areas such as respiratory health, cardiovascular care, and anti-diabetic medications. With 15 manufacturing sites and seven research centers worldwide, Lupin employs over 23,000 individuals. Despite the positive news of the partnership, Lupin’s shares closed lower on the NSE at ₹1,969.50, showing a decrease of ₹60.10 or 2.96%. The company’s focus on sustainability and innovation continues to drive their efforts in the pharmaceutical industry, setting them apart from their competitors.